GLP-1 Medications and Type 2 Diabetes: What People With Prediabetes Need to Know

GLP-1 Medications and Type 2 Diabetes: What People With Prediabetes Need to Know

If you have prediabetes and are struggling with your weight, you’re at a critical juncture. The window to prevent type 2 diabetes is real — and GLP-1 receptor agonists may be one of the most powerful tools available to you. These medications, now famous for weight loss, were originally developed to treat type 2 diabetes, and they have impressive credentials when it comes to blood sugar management.

This article explains what people with prediabetes need to know about GLP-1 medications: how they work on blood sugar, what the research shows, whether you can qualify for them, and what to expect if you start treatment.

What Is Prediabetes and Why Does It Matter?

Prediabetes is a metabolic state in which blood sugar levels are higher than normal but not yet in the type 2 diabetes range. Diagnosis is typically made when:

• Fasting blood glucose is 100–125 mg/dL (normal is under 100)
• A1c is 5.7–6.4% (diabetes is 6.5% or higher)
• 2-hour glucose during an oral glucose tolerance test is 140–199 mg/dL

An estimated 96 million American adults — roughly 1 in 3 — have prediabetes. Without intervention, about 15–30% will progress to type 2 diabetes within 5 years. The stakes are high: type 2 diabetes is associated with heart disease, kidney disease, nerve damage, vision loss, and shortened life expectancy.

But here’s the critical point: prediabetes is reversible. With meaningful weight loss (even 5–7% of body weight), regular physical activity, and blood sugar management, many people fully normalize their blood glucose. GLP-1 medications make that weight loss dramatically more achievable.

How GLP-1 Medications Improve Blood Sugar

GLP-1 receptor agonists improve blood sugar through several complementary mechanisms:

Glucose-Dependent Insulin Stimulation

GLP-1 stimulates insulin release from the pancreas — but only when blood glucose is elevated. This “glucose-dependent” mechanism is what makes GLP-1 drugs very safe from a hypoglycemia standpoint. Unlike some older diabetes medications, GLP-1 agonists don’t trigger dangerous blood sugar drops when glucose is already normal.

Glucagon Suppression

Glucagon is a hormone that tells the liver to release stored glucose into the bloodstream. GLP-1 medications suppress glucagon, reducing this unnecessary glucose output — a key problem in both prediabetes and type 2 diabetes.

Slowed Gastric Emptying

By slowing how quickly food leaves the stomach, GLP-1 drugs reduce the post-meal glucose spike. This is especially beneficial for people with prediabetes, in whom these spikes are often the earliest detectable metabolic abnormality.

Weight Loss

Perhaps the most impactful mechanism for prediabetes is simply the weight loss these drugs produce. Fat — especially visceral abdominal fat — is highly insulin resistant. As it’s lost, insulin sensitivity improves dramatically, often normalizing blood sugar completely.

What the Research Shows for Prediabetes and Diabetes Prevention

The evidence is compelling. In the SUSTAIN 6 and LEADER trials (studying semaglutide and liraglutide respectively in people with type 2 diabetes), participants showed not only better blood sugar control but significantly reduced rates of cardiovascular events.

More relevant for prediabetes, the SELECT trial — which studied semaglutide 2.4mg (Wegovy) in people with obesity and cardiovascular disease but NOT diabetes — found that the drug reduced new-onset diabetes by approximately 73% compared to placebo over three years. This is one of the most dramatic diabetes prevention results ever observed in a large clinical trial.

For reference, the gold-standard Diabetes Prevention Program (DPP) lifestyle intervention reduces diabetes risk by about 58% — impressive, but less than what semaglutide achieved pharmacologically in SELECT.

Can You Get GLP-1 Medications for Prediabetes?

Here’s where it gets nuanced. In the United States, the FDA-approved weight loss versions of GLP-1 medications (Wegovy, Zepbound) are indicated for people with:

• BMI ≥ 30 (obesity), OR
• BMI ≥ 27 (overweight) plus at least one weight-related health condition — which includes prediabetes

This means if you have a BMI of 27 or higher and prediabetes, you may qualify for Wegovy or Zepbound based on approved indications. Your prescriber can prescribe these for you.

Insurance coverage is another matter. While Medicare coverage for weight loss medications has improved, many commercial insurance plans still have inconsistent coverage. However, being able to document prediabetes (or other conditions like hypertension, dyslipidemia, or sleep apnea) alongside obesity can strengthen your case for prior authorization.

What to Monitor on GLP-1 Therapy If You Have Prediabetes

Regular A1c and Fasting Glucose Testing

Your provider should check your A1c and fasting glucose at baseline and at 3–6 month intervals during GLP-1 treatment. For many people with prediabetes, these numbers improve significantly — sometimes normalizing — within the first 6–12 months on medication.

Watch for Hypoglycemia (It’s Rare But Possible)

While GLP-1 medications alone rarely cause low blood sugar, if you’re also taking other glucose-lowering medications (like metformin plus a sulfonylurea), there’s a theoretical interaction risk. Discuss all your medications with your provider.

Track Your Weight and Lifestyle

The medication is most effective when paired with dietary changes and physical activity. For prediabetes specifically, resistance training that builds muscle mass is especially valuable — muscle is the body’s primary glucose-disposal organ, and more of it dramatically improves insulin sensitivity.

Will You Need to Stay on GLP-1 Medication Forever?

This is a question many people ask, and the honest answer is: it depends. GLP-1 medications produce their blood sugar and weight benefits primarily while you’re taking them. Stopping often leads to weight regain and return of elevated blood sugar.

However, some people use GLP-1 therapy as a “reset” — using the weight loss period to build lasting lifestyle habits, achieve significant metabolic improvement, and then maintain their health with a combination of diet, exercise, and potentially a lower maintenance dose or different medication. Your long-term plan should be something you discuss explicitly with your provider.

The Bottom Line

If you have prediabetes and excess weight, GLP-1 medications represent one of the most evidence-backed interventions available to prevent progression to type 2 diabetes. They work through multiple blood sugar pathways, produce meaningful weight loss, and may dramatically reduce your lifetime diabetes risk.

The key is to act while you still have the opportunity to reverse the trajectory. Talk to your doctor about whether you qualify, what your monitoring plan should look like, and how to combine medication with lifestyle changes for the best long-term outcomes. Prediabetes doesn’t have to become type 2 diabetes — and GLP-1 therapy can be a powerful ally in preventing that future.